[Economic assessment of efficacy of vasaprostan treatment of critical lower limbs ischemia].
OBJECTIVE
To estimate cost-effect efficacy of vasaprostan treatment of inpatients with arterial chronic obliteration (ACO) with critical ischemia of the lower limbs (Fonten stage III-IV).


METHODS
Case histories of 105 ACO patients with critical ischemia of the lower limbs (mean age 65 +/- 11.8 years) were analysed to compare efficacy and cost of the "typical practice" of hospital treatment of such patients with prognostic cost of basaprostan treatment using drug-cost modeling.


RESULTS
The cost-effect analysis comparing efficacy of "typical practice" and vasaprostan treatment showed that in "typical practice" amputations of the limb are inevitable in 41% while vasaprostan treatment reduces the percentage of the operations to 8.6-12% (according to the literature); overall cost of the "typical" treatment for 105 patients reached 3,909,222 roubles while relevant prognostic cost of vasaprostan treatment made up 4,407,162-4,570,653 roubles. Thus, vasaprostan treatment is characterized by less expense per 1 case of the limb amputation prevention vs "typical practice".


CONCLUSIONS
The models used demonstrated that vasaprostan treatment is more cost-effective than "typical practice".
Vorob'ev
P A
PA
Dergach
E V
EV
Gerasimov
V B
VB
Avksent'eva
M V
MV
D000368:Aged; D000369:Aged, 80 and over; D000527:Alprostadil / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006801:Humans; D007511:Ischemia / Q000188:drug therapy / Q000191:economics*; D007866:Leg / Q000098:blood supply*; D008875:Middle Aged; D014665:Vasodilator Agents / Q000191:economics* / Q000627:therapeutic use
D014665:Vasodilator Agents; D000527:Alprostadil